Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics

被引：0

作者：

窦雪琳 ^{[1
]}

机构：

[1] Peking Univ People’s Hosp,Peking Univ Hematol Instit

来源：

China Medical Abstracts(Internal Medicine) | 2020年 / 37卷 / 01期

关键词：

Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics;

D O I：

暂无

中图分类号：

R733.72 [慢性白血病];

学科分类号：

摘要：

Objective To compare the efficacy and safety of Chinese generic imatinib with branded imatinib as frontline therapy in adults with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)(Frontline group),and to explore the efficacy and safety of Chinese generic imatinib in CML-CP patients switching from branded imatinib (Switching group).Methods Frontline group:Data of adults with newly diagnosed CML-CP re-

引用

页码：59 / 60

页数：2

共 50 条

[31] Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population
Zhao, Yanmin
Liu, Lizhen
Wang, Yingjia
Wu, Gongqiang
Lai, Xiaoyu
Cao, Weijie
Luo, Yi
Tan, Yamin
Shi, Jimin
Xie, Wanzhuo
Ye, Xiujin
Cai, Zhen
Lin, Maofang
Huang, He
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (04) : 445 - 451
[32] Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia
Hyejin Shin
Soo Young Choi
Kyung-Mi Kee
Soo-Hyun Kim
Seon-Young Yang
Su Young Jung
Hayeon Noh
Dae Young Zang
Dong-Wook Kim
Jangik I. Lee
International Journal of Hematology, 2020, 111 : 417 - 426
[33] Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia
Shin, Hyejin
Choi, Soo Young
Kee, Kyung-Mi
Kim, Soo-Hyun
Yang, Seon-Young
Jung, Su Young
Noh, Hayeon
Zang, Dae Young
Kim, Dong-Wook
Lee, Jangik, I
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (03) : 417 - 426
[34] Efficacy of Imatinib Dose Escalation in Patients With Chronic Myeloid Leukemia in Chronic Phase
Kantarjian, Hagop M.
Larson, Richard A.
Guilhot, Francois
O'Brien, Stephen G.
Mone, Manisha
Rudoltz, Marc
Krahnke, Tillmann
Cortes, Jorge
Druker, Brian J.
CANCER, 2009, 115 (03) : 551 - 560
[35] Imatinib in chronic myeloid leukemia elderly patients
Gugliotta, Gabriele
Castagnetti, Fausto
Palandri, Francesca
Baccarani, Michele
Rosti, Gianantonio
AGING-US, 2011, 3 (12): : 1125 - 1126
[36] Imatinib monitoring in chronic myeloid leukemia patients
Kilic, P.
Kayaalti, Z.
Gunduz, M.
Gurman, G.
Soylemezoglu, T.
TOXICOLOGY LETTERS, 2015, 238 (02) : S241 - S241
[37] Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia
Klil-Drori, Adi J.
Azoulay, Laurent
Yin, Hui
Gratton, Michel-Olivier
Harnois, Michael
Chamakhi, Ines
Delage, Robert
Laneuville, Pierre
Mollica, Luigina
Olney, Harold J.
Busque, Lambert
Assouline, Sarit E.
BLOOD, 2015, 126 (23)
[38] Fertility in patients on imatinib for chronic myeloid leukemia
Siddique, M. K.
Siddiqui, N.
Mahmood, R.
Rehan, H.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[39] PLASMATIC LEVELS, RESPONSE AND TOLERANCE TO IMATINIB AFTER THE CHANGE OF GLIVEC TO GENERIC IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
Wojnicz, A.
Cornago Navascues, J.
Vaitekovich, V.
Mba, C.
Sola Aparicio, E.
Steegmann Olmedillas, J. L.
HAEMATOLOGICA, 2018, 103 : 232 - 232
[40] Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia-Single Center Retrospective Analysis
Bhatwadekar, Seema Shrinivas
Deshpande, Shubhangi Vishwas
Mehta, Arpan
Shah, Parth
BLOOD, 2019, 134

← 1 2 3 4 5 →